TY - JOUR
T1 - Assessment of patients with neuromyelitis optica spectrum disorder using the EQ-5D
AU - Mealy, Maureen A.
AU - Boscoe, Audra
AU - Caro, Jaime
AU - Levy, Michael
N1 - Funding Information:
Funding/Support: This work was supported by Alexion Pharmaceuticals. No one from Alexion was involved in data collection.
Funding Information:
Continuing Education Supplement to the International Journal of MS Care This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.
Funding Information:
Ms. Mealy is a PhD candidate at the Johns Hopkins University School of Nursing. Dr. Boscoe works for Alexion Pharmaceuticals. Dr. Levy currently receives research support from the National Institutes of Health, Maryland Technology Development Corporation, Sanofi, Genzyme, Alexion, Alnylam, Shire, Acorda, and Apopharma; has received personal compensation for consultation from Alexion, Acorda, and Genzyme; and serves on the scientific advisory boards for Alexion, Acorda, and Quest Diagnostics. The other authors declare no conflicts of interest. This work was supported by Alexion Pharmaceuticals. No one from Alexion was involved in data collection
Publisher Copyright:
© 2019 Consortium of Multiple Sclerosis Centers.
PY - 2019/5/1
Y1 - 2019/5/1
N2 - Background: Neuromyelitis optica spectrum disorder (NMOSD) is a rare autoimmune disease characterized by unpredictable attacks of the optic nerves and spinal cord that cause neurologic deficits, including weakness, numbness, bowel/bladder dysfunction, and pain and reduced vision and can ultimately lead to blindness and paralysis. We assessed the effects of NMOSD on quality of life. Methods: Adult patients with NMOSD treated at a US academic neurology clinic completed the EQ-5D and several other measures of functional status and quality of life. The EQ-5D scores and correlations across measures were evaluated, and scores were compared with those of patients with multiple sclerosis and US norms. Results: Twenty-one patients (90% women; mean age, 42.8 years; mean disease duration, 8.2 years) were included. The mean EQ-5D score was 0.74. Most patients reported at least some problems with mobility, pain/discomfort, usual activities, and/or anxiety/depression. Greater proportions of patients reported moderate or severe problems with mobility and pain/discomfort than they did with self-care, usual activities, or anxiety/depression. In a multivariate model, only the Brief Pain Inventory was a significant independent predictor of overall EQ-5D score. Conclusions: Neuromyelitis optica spectrum disorder has a substantial effect on multiple domains of quality of life. Pain seems to be among the primary drivers of the EQ-5D scores in NMOSD.
AB - Background: Neuromyelitis optica spectrum disorder (NMOSD) is a rare autoimmune disease characterized by unpredictable attacks of the optic nerves and spinal cord that cause neurologic deficits, including weakness, numbness, bowel/bladder dysfunction, and pain and reduced vision and can ultimately lead to blindness and paralysis. We assessed the effects of NMOSD on quality of life. Methods: Adult patients with NMOSD treated at a US academic neurology clinic completed the EQ-5D and several other measures of functional status and quality of life. The EQ-5D scores and correlations across measures were evaluated, and scores were compared with those of patients with multiple sclerosis and US norms. Results: Twenty-one patients (90% women; mean age, 42.8 years; mean disease duration, 8.2 years) were included. The mean EQ-5D score was 0.74. Most patients reported at least some problems with mobility, pain/discomfort, usual activities, and/or anxiety/depression. Greater proportions of patients reported moderate or severe problems with mobility and pain/discomfort than they did with self-care, usual activities, or anxiety/depression. In a multivariate model, only the Brief Pain Inventory was a significant independent predictor of overall EQ-5D score. Conclusions: Neuromyelitis optica spectrum disorder has a substantial effect on multiple domains of quality of life. Pain seems to be among the primary drivers of the EQ-5D scores in NMOSD.
UR - http://www.scopus.com/inward/record.url?scp=85065590318&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85065590318&partnerID=8YFLogxK
U2 - 10.7224/1537-2073.2017-076
DO - 10.7224/1537-2073.2017-076
M3 - Article
C2 - 31191178
AN - SCOPUS:85065590318
SN - 1537-2073
VL - 21
SP - 129
EP - 134
JO - International Journal of MS Care
JF - International Journal of MS Care
IS - 3
ER -